Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

393
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

118
Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

PROTHROMBIN, FACTOR-V LEIDEN, AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 GENE POLYMORPHISMS IN HEMODIALYSIS PATIENTS WITH/WITHOUT ARTERIOVENOUS FISTULA THROMBOSIS

Pages

  314-319

Abstract

 Background and Aims: FACTOR V LEIDEN MUTATION (G1691A) has been recognized to be the most prevalent genetic risk factor for venous thrombosis. Other common risk factor for venous thrombosis is Prothrombin 20210 G-A alteration, which causes a gain of function in the coagulation system with an increase of prothrombin levels, associated with an increased potential to form thrombin. Plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism is the most frequently studied in thrombotic events. Aim of this study was to investigate the relationship between these polymorphisms and arteriovenousfistula (AVF) thrombosis in HEMODIALYSIS (HD) patients.Methods: The study included 31 HD patients with AVF thrombosis and 51 HD patients without AVF thrombosis.DNA was extracted from peripheral blood samples from the patient and control groups. Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods were used to identify the polymorphisms.Results: There were no significant differences between HD patients with and without AVF thrombosis in terms of Factor V Leiden and PROTHROMBIN G20210A MUTATIONs. PAI-1 4G allele in heterozygous state have an effect on the thrombosis risk in HD patients (O.R=4.271).Conclusions: Only carrying PAI-1 4G/5G genotype had an additional risk for thrombosis in HD patients.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    EMIROGULLARI, ELIF FUNDA, SAATCI, CETIN, UNAL, AYDIN, SAHIN, ATILLA, & OZKUL, YUSUF. (2010). PROTHROMBIN, FACTOR-V LEIDEN, AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 GENE POLYMORPHISMS IN HEMODIALYSIS PATIENTS WITH/WITHOUT ARTERIOVENOUS FISTULA THROMBOSIS. THE JOURNAL OF NEPHRO-UROLOGY MONTHLY, 2(2), 314-319. SID. https://sid.ir/paper/323723/en

    Vancouver: Copy

    EMIROGULLARI ELIF FUNDA, SAATCI CETIN, UNAL AYDIN, SAHIN ATILLA, OZKUL YUSUF. PROTHROMBIN, FACTOR-V LEIDEN, AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 GENE POLYMORPHISMS IN HEMODIALYSIS PATIENTS WITH/WITHOUT ARTERIOVENOUS FISTULA THROMBOSIS. THE JOURNAL OF NEPHRO-UROLOGY MONTHLY[Internet]. 2010;2(2):314-319. Available from: https://sid.ir/paper/323723/en

    IEEE: Copy

    ELIF FUNDA EMIROGULLARI, CETIN SAATCI, AYDIN UNAL, ATILLA SAHIN, and YUSUF OZKUL, “PROTHROMBIN, FACTOR-V LEIDEN, AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 GENE POLYMORPHISMS IN HEMODIALYSIS PATIENTS WITH/WITHOUT ARTERIOVENOUS FISTULA THROMBOSIS,” THE JOURNAL OF NEPHRO-UROLOGY MONTHLY, vol. 2, no. 2, pp. 314–319, 2010, [Online]. Available: https://sid.ir/paper/323723/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top